What is the 13F Pro Quality Score for BCAX?

13F Pro ranks Bicara Therapeutics Inc. (BCAX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCAX's current score at https://13fpro.ai/research/BCAX (free sign-up required for the full ranking).

Which hedge funds own the most BCAX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BCAX include RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Vestal Point Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BCAX as soon as new 13F filings post.

Where does 13F Pro source BCAX data?

All Bicara Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Bicara Therapeutics Inc. files with the SEC under CIK 2023658. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCAX in?

Bicara Therapeutics Inc. (BCAX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BCAX research updated on 13F Pro?

BCAX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Bicara Therapeutics Inc.(BCAX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 2023658 BCAX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BCAX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Bicara Therapeutics Inc. (BCAX), a Healthcare sector company. BCAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Bicara Therapeutics Inc. reports net income of $-56.2M, free cash flow of $-37.6M. Top institutional holders of BCAX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Vestal Point Capital,, based on the most recent SEC filings. BCAX trades on the Nasdaq exchange and files with the SEC under CIK 2023658. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bicara Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-56.2M

Free Cash Flow

Q1 2026

$-37.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-102.9% YoY

$-137.9MFY 2025

FY23 $-52.0MFY24 $-68.0MFY25 $-137.9M

Operating Income

-88.9% YoY

$-155.6MFY 2025

FY23 $-39.9MFY24 $-82.4MFY25 $-155.6M

EPS (Diluted)

+37.8% YoY

$-2.52FY 2025

FY23 $-1.05FY24 $-4.05FY25 $-2.52

Total Assets

-15.5% YoY

$431.0MFY 2025

FY23 $234.0MFY24 $510.0MFY25 $431.0M

Op. Cash Flow

-42.9% YoY

$-106.8MFY 2025

FY23 $-45.6MFY24 $-74.8MFY25 $-106.8M

Metric	FY 2025	FY 2024	FY 2023
Net Income	$-137.9M -102.9%	$-68.0M -30.8%	$-52.0M
Operating Income	$-155.6M -88.9%	$-82.4M -106.5%	$-39.9M
EPS (Diluted)	$-2.52 +37.8%	$-4.05 -284.2%	$-1.05
Total Assets	$431.0M -15.5%	$510.0M +118.0%	$234.0M
Operating Cash Flow	$-106.8M -42.9%	$-74.8M -63.8%	$-45.6M

AI Insight: BCAX Financial Trends

A $345M equity raise in Q1 2026 offset a sharp loss acceleration, but quarterly cash burn hit a new high of $38M.

• Equity jumped from $401M in Q4 2025 to $514M in Q1 2026, implying a significant capital raise despite widening losses.

• Operating loss widened sharply to $60M in Q1 2026 from $41M in Q4 2025, the largest single-quarter loss on record.

• Operating cash outflow reached $38M in Q1 2026, the highest in the tracked period, versus a range of $24M–$30M in prior quarters.

⚠ With no revenue and quarterly burn now at $38M, runway duration depends entirely on timing and size of future capital raises.

⚠ The step-up in Q1 2026 operating losses to $60M warrants scrutiny — monitor whether this reflects a one-time spike or a new baseline.

AI Insight: BCAX Ratio Trends

BCAX's capital returns are deteriorating sharply, with ROIC worsening from -21.7% in Q4 2024 to -46.9% in Q1 2026 as the pre-revenue biotech burns cash.

• ROIC deteriorated steadily from -21.7% in Q4 2024 to -46.9% in Q1 2026, a 25pp decline over five quarters.

• ROE fell from -17.0% in Q4 2024 to -43.8% in Q1 2026, signaling accelerating equity erosion.

• ROA dropped from -16.4% in Q4 2024 to -40.6% in Q1 2026, reflecting rising asset-intensity relative to losses.

⚠ ROIC hit -46.9% in Q1 2026 — the worst reading in the dataset; cash runway and burn rate are critical to monitor.

⚠ OpMargin and NPM remain entirely absent across all periods, limiting visibility into operating cost structure.

Get alerted when BCAX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bicara Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCAX

RA CAPITAL MANAGEMENT, L.P.
$144.3M7,255,993 sh
Siren, L.L.C.
$115.4M5,802,970 sh
Vestal Point Capital, LP
$107.9M5,425,000 sh
Deep Track Capital, LP
$80.8M4,062,500 sh
JANUS HENDERSON GROUP PLC
$66.1M3,326,918 sh
Red Tree Management, LLC
$63.1M3,170,509 sh
TPG GP A, LLC
$59.9M3,010,425 sh
BlackRock, Inc.
$56.6M2,843,707 sh
Omega Fund Management, LLC
$47.6M2,392,150 sh
Royalty Pharma Sub-Manager, LLC
$46.7M2,388,150 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$144.3M	7,255,993
Siren, L.L.C.	$115.4M	5,802,970
Vestal Point Capital, LP	$107.9M	5,425,000
Deep Track Capital, LP	$80.8M	4,062,500
JANUS HENDERSON GROUP PLC	$66.1M	3,326,918
Red Tree Management, LLC	$63.1M	3,170,509
TPG GP A, LLC	$59.9M	3,010,425
BlackRock, Inc.	$56.6M	2,843,707
Omega Fund Management, LLC	$47.6M	2,392,150
Royalty Pharma Sub-Manager, LLC	$46.7M	2,388,150

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCAX on your watchlist

Track score changes the day Bicara Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCAX a good stock to buy?

13F Pro's AI-powered analysis of Bicara Therapeutics Inc. (BCAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCAX are available on the BCAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BCAX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bicara Therapeutics Inc.'s investment landscape.